Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[A man in his 50s with acute renal failure, anemia, and thrombocytopenia].

Marthe Kopland1, Vigdis Skinnemoen Ottersen2, Dag Olav Dahle3

  • 1Medisinsk avdeling, Drammen sykehus.

Tidsskrift for Den Norske Laegeforening : Tidsskrift for Praktisk Medicin, Ny Raekke
|January 21, 2025
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A holistic prognostic model for leukemia-free survival after allogeneic transplantation in acute leukemia.

Bone marrow transplantation·2026
Same author

Allogeneic hematopoietic cell transplantation for T-cell/histiocyte-rich large B-cell lymphoma: An EBMT lymphoma working party study.

Leukemia·2026
Same author

Trends in Transplantation for Myelodysplastic Syndrome Patients Across Recent Decades: A Registry-Based Study on Behalf of the Chronic Malignancies Working of the EBMT.

American journal of hematology·2026
Same author

Plasma Levels of Retinoids and Carotenoids in Recipients of Allogeneic Hematopoietic Stem Cell Transplantation Given Extracorporeal Photopheresis to Prevent Graft-Versus-Host Disease-Analyses From a Randomized Trial.

EJHaem·2026
Same author

Long-term outcome of allogeneic hematopoietic cell transplantation for T-cell prolymphocytic leukemia - a study on behalf of the Chronic Malignancies Working Party of the EBMT.

Haematologica·2026
Same author

Long-term HIV-1 remission achieved through allogeneic haematopoietic stem cell transplant from a CCR5Δ32/Δ32 sibling donor.

Nature microbiology·2026

Thrombotic microangiopathy (TMA) requires careful diagnosis to distinguish between various syndromes. Prompt identification of Shiga toxin-induced hemolytic uremic syndrome (ST-HUS) is crucial for appropriate patient management and avoiding unnecessary treatments.

Area of Science:

  • Nephrology
  • Hematology
  • Internal Medicine

Background:

  • Thrombotic microangiopathy (TMA) is characterized by hemolytic anemia, thrombocytopenia, and renal failure.
  • Differential diagnoses of primary TMA syndromes, their clinical findings, workup, and treatment are complex.
  • Overlapping clinical features often make TMA diagnosis challenging.

Purpose of the Study:

  • To describe the differential diagnoses of primary TMA syndromes.
  • To outline the clinical findings, workup, and treatment strategies for TMA.
  • To highlight the importance of accurate diagnosis to avoid inappropriate treatments.

Main Methods:

  • Case presentation of a patient with suspected TMA.
  • Diagnostic workup including ADAMTS13 level assessment and fecal sampling for EHEC DNA.

Related Experiment Videos

  • Therapeutic interventions including plasma exchange, hemodialysis, and eculizumab administration.

    • Main Results:

    • Initial suspicion of thrombotic thrombocytopenic purpura (TTP) was ruled out by normal ADAMTS13 levels.
    • Diagnosis of Shiga toxin-induced hemolytic uremic syndrome (ST-HUS) was confirmed by detecting EHEC DNA.
    • Patient's renal function normalized with supportive care.

    Conclusions:

    • Accurate differentiation between TMA syndromes is essential for effective treatment.
    • Shiga toxin-induced hemolytic uremic syndrome (ST-HUS) should be considered in cases of TMA, especially with EHEC detection.
    • Timely and correct diagnosis can prevent the use of potentially harmful and unnecessary therapies.